CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
2018 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
Ermann, N.; Lewczuk, P.; Schmitz, M.; Lange, P.; Knipper, T.; Goebel, S. & Kornhuber, J. et al. (2018)
Annals of Clinical and Translational Neurology, 5(7) pp. 883-887. DOI: https://doi.org/10.1002/acn3.584
Documents & Media
Details
- Authors
- Ermann, Natalia; Lewczuk, Piotr; Schmitz, Matthias; Lange, Peter; Knipper, Tobias; Goebel, Stefan; Kornhuber, Johannes; Zerr, Inga; Llorens, Franc
- Abstract
- Abstract Creutzfeldt–Jakob disease and Alzheimer's disease are characterized by the presence of elevated total‐Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho‐Tau epitopes (non‐P‐Tau) in the discrimination between both diseases. Non‐P‐Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt–Jakob disease ( n = 57, 3683 ± 3599 pg/ mL ) compared to Alzheimer's disease ( n = 41, 148 ± 219 pg/ mL ) and neurological controls ( n = 56, 62 ± 40 pg/ mL ), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total‐Tau (90%), P‐Tau (62%) and 14‐3‐3 (91%).
- Issue Date
- 2018
- Journal
- Annals of Clinical and Translational Neurology
- ISSN
- 2328-9503
- eISSN
- 2328-9503
- Language
- English
- Sponsor
- Bundesministerium für Gesundheit https://doi.org/10.13039/501100003107
Seventh Framework Programme https://doi.org/10.13039/100011102
